Cellular immunity and active human cytomegalovirus infection in patients with septic shock

Journal of Infectious Diseases

Volumn 196, Issue 9, 2007, Pages 1288-1295

  Von Müller, Lutz ^a,b   Klemm, Anke ^a   Durmus, Nilgün ^a   Weiss, Manfred ^a   Suger Wiedeck, Heide ^a   Schneider, Marion ^a   Hampl, Walter ^a   Mertens, Thomas ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CATECHOLAMINE DERIVATIVE; CD16 ANTIGEN; CD56 ANTIGEN; CORTISONE; INTERLEUKIN 2; STAPHYLOCOCCUS ENTEROTOXIN B;

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; CELL ACTIVITY; CELL FUNCTION; CELL INTERACTION; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; SEPTIC SHOCK; TH1 CELL; VIRUS REACTIVATION; IMMUNOLOGY; MIDDLE AGED; NATURAL KILLER CELL; PHYSIOLOGY; TIME;

ADULT; AGED; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; IMMUNITY, CELLULAR; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; SHOCK, SEPTIC; TH1 CELLS; TIME FACTORS;

EID: 38449113163     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/522429     Document Type: Article

References (33)

1. Pass RF. Cytomegalovirus. In: Knipe DM, Howley PM, eds. Fields virology. Philadelphia: Lippincott Williams & Wilkins, 2001:2675-705.
2. Asanuma H, Sharp M, Maecker HT, Maino VC, Arvin AM. Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression. J Infect Dis 2000; 181:859-66.
3. Hertenstein B, Hampl W, Bunjes D, et al. In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT. Bone Marrow Transplant 1995; 15:387-93.
4. Cerboni C, Mousavi-Jazi M, Linde A, et al. Human cytomegalovirus strain-dependent changes in NK cell recognition of infected fibroblasts. J Immunol 2000; 164:4775-82.
5. Cook M, Briggs D, Craddock C, et al. Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation. Blood 2006; 107:1230-2.
6. Boeckh M, Boivin G. Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin Microbiol Rev 1998; 11:533-54.
7. Kutza AST, Muhl E, Hackstein H, Kirchner H, Bein G. High incidence of active cytomegalovirus infection among septic patients. Clin Infect Dis 1998; 26:1076-82.
8. Barry SM, Johnson MA, Janossy G. Cytopathology or immunopathology? The puzzle of cytomegalovirus pneumonitis revisited. Bone Marrow Transplant 2000; 26:591-7.
9. Curtsinger LJ, Cheadle WG, Hershman MJ, Cost K, Polk HC Jr. Association of cytomegalovirus infection with increased morbidity is independent of transfusion. Am J Surg 1989; 158:606-10.
10. Heininger A, Jahn G, Engel C, Notheisen T, Unertl K, Hamprecht K. Human cytomegalovirus infections in nonimmunosuppressed critically ill patients. Crit Care Med 2001; 29:541-7.
11. Cook CH, Martin LC, Yenchar JK, et al. Occult herpes family viral infections are endemic in critically ill surgical patients. Crit Care Med 2003; 31:1923-9.
12. von Müller L, Klemm A, Weiss M, et al. Active cytomegalovirus infection in patients with septic shock. Emerg Infect Dis 2006; 12:1517-22.
13. American College of Chest Physicians/Society of Critical Care Medicine consensus conference: definitions for sepsis and organ failure guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-74.
14. Riedemann NC, Guo RF, Ward PA. The enigma of sepsis. J Clin Invest 2003; 112:460-7.
15. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31:1250-6.
16. Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996; 24:1125-8.
17. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348:138-50.
18. von Müller L, Hampl W, Hinz J, et al. High variability between results of different in-house tests for cytomegalovirus (CMV) monitoring and a standardized quantitative plasma CMV PCR assay. J Clin Microbiol 2002; 40:2285-7.
19. Waner JL, Budnick JE. Blastogenic response of human lymphocytes to human cytomegalovirus. Clin Exp Immunol 1977; 30:44-9.
20. Sester M, Gartner BC, Sester U, Girndt M, Mueller-Lantzsch N, Kohler H. Is the cytomegalovirus serologic status always accurate? A comparative analysis of humoral and cellular immunity. Transplantation 2003; 76:1229-30.
21. Puente J, Carvajal T, Parra S, et al. In vitro studies of natural killer cell activity in septic shock patients: response to a challenge with alpha-interferon and interleukin-2. Int J Clin Pharmacol Ther Toxicol 1993; 31:271-5.
22. Piriou L, Chilmonczyk S, Genetet N, Albina E. Design of a flow cytometric assay for the determination of natural killer and cytotoxic Tlymphocyte activity in human and in different animal species. Cytometry 2000; 41:289-97.
23. Vincent J-L, Moreno R, Takala J, et al. The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22:707-10.
24. Reinke P, Prösch S, Kern F, Volk H-D. Mechanisms of human cytomegalovirus (HCMV) (re)activation and its impact on organ transplant patients. Transpl Infect Dis 1999; 1:157-64.
25. + monocytes is differentiation dependent. J Virol 2001; 75:7543-54.
26. Cook CH, Trgovcich J, Zimmerman PD, Zhang Y, Sedmak DD. Lipopolysaccharide, tumor necrosis factor alpha, or interleukin-1beta triggers reactivation of latent cytomegalovirus in immunocompetent mice. J Virol 2006; 80:9151-8.
27. Reusser P, Attenhofer R, Hebart H, Helg C, Chapuis B, Einsele H. Cytomegalovirus-specific T-cell immunity in recipients of autologous peripheral blood stem cell or bone marrow transplants. Blood 1997; 89:3873-9.
28. Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002; 99:3916-22.
29. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002; 298:2199-202.
30. Cook CH, Zhang Y, Sedmak DD, Martin LC, Jewell S, Ferguson RM. Pulmonary cytomegalovirus reactivation causes pathology in immunocompetent mice. Crit Care Med 2006; 34:842-9.
31. Sester M, Sester U, Alarcon SS, et al. Age-related decrease in adenovirus-specific T cell responses. J Infect Dis 2002; 185:1379-87.
32. Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat Med 2003; 9:517-24.
33. Vredevoe DL, Widawski M, Fonarow GC, Hamilton M, Martinez-Maza O, Gage JR. Interleukin-6 (IL-6) expression and natural killer (NK) cell dysfunction and anergy in heart failure. Am J Cardiol 2004; 93:1007-11.